drugset / Trial / NCT04624841

Indocyanine Green to Visualize Critical View of Safety During Laparoscopic Cholecystectomy for Acute Cholecystitis

NCT04624841

Phase 4 Unknown 80 enrolled Hamad Medical Corporation
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

The purpose of this prospective randomized trial is to study the role of Indocyanine green (ICG) to visualize the Critical View of Safety during emergency Laparoscopic Cholecystectomy for patients with Acute Cholecystitis.

Timeline

Start
2021-01-01
Primary completion
2021-12-31
Completion
2022-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.05 mg/kg Intravenous

Indications